Anzeige
Mehr »
Login
Mittwoch, 22.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die Wachstumsgeschichte: Analysten sehen kurzfristige +37 %-Chance bei diesem europäischen Marktführer
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EKLV | ISIN: US35168W1036 | Ticker-Symbol:
NASDAQ
21.05.24
21:58 Uhr
7,270 US-Dollar
+0,300
+4,30 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FRACTYL HEALTH INC Chart 1 Jahr
5-Tage-Chart
FRACTYL HEALTH INC 5-Tage-Chart

Aktuelle News zur FRACTYL HEALTH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoFractyl Health, Inc.: Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva at Digestive Disease Week 202426Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein...
► Artikel lesen
13.05.Fractyl Health reports Q1 results1
13.05.FRACTYL HEALTH, INC. - 10-Q, Quarterly Report1
13.05.Fractyl Health, Inc.: Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates568Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal...
► Artikel lesen
13.05.FRACTYL HEALTH, INC. - 8-K, Current Report1
13.05.Fractyl Health, Inc.: Fractyl Health Presents Clinical Update on Revita German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)40First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita...
► Artikel lesen
08.05.Fractyl Health, Inc.: Fractyl Health to Present at BofA Securities 2024 Health Care Conference1
07.05.Fractyl Health, Inc.: Fractyl Health to Report First Quarter 2024 Financial Results and Provide Business Updates on May 13, 20241
30.04.Fractyl Health, Inc.: Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting1
02.04.Fractyl Health, Inc.: Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes68BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of...
► Artikel lesen
01.04.Fractyl Health slumps after wider Q4 loss2
01.04.Fractyl Health gains after FDA allows study of weight management device2
01.04.Fractyl Health, Inc.: Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update199Received IDE approval for the Revita® Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 Based Drugs Completion of enrollment in pivotal Revitalize-1...
► Artikel lesen
01.04.Fractyl Health Gets IDE Approval To Study Revita's Efficacy In Maintaining Weight Loss2
01.04.FRACTYL HEALTH, INC. - 10-K, Annual Report1
01.04.Fractyl Health, Inc.: Fractyl Health Receives FDA IDE Approval for the Revita Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs71Revita aims to be the first approved therapeutic option for durable weight maintenance after discontinuation of GLP-1 based drugs, as an adjunct to diet and exercise With this FDA IDE approval, Fractyl...
► Artikel lesen
01.04.FRACTYL HEALTH, INC. - 8-K, Current Report1
12.03.Fractyl stock slides amid preclinical data for diabetes gene therapy2
12.03.Newly Listed Obesity Player Fractyl Health Shares Encouraging Preclinical Data1
12.03.US STOCKS Madrigal Pharmaceuticals, Coinbase, Fractyl21
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1